Abbvie

This study tests a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) in people with advanced pancreatic cancer that has spread. About 900 adults will be randomly assigned to receive either the new combination or standard treatment. The goal is to se…

This study tests whether adding a new drug called pivekimab sunirine to two standard medicines (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants worldwide will …

This study tests an experimental drug called ABBV-1758 in about 210 adults with early Alzheimer's disease. The drug is given as an infusion or injection every 4 weeks for 24 weeks. Researchers will check for side effects and measure changes in brain amyloid plaques using PET scan…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or one of three usual drugs (topotecan, lurbinectedin, or amrubicin) to see which works better and…

This study tests a single gene therapy injection (sura-vec) for people with diabetic retinopathy, a common diabetes complication that can damage the retina and cause vision loss. About 576 adults with moderate-to-severe non-proliferative diabetic retinopathy will receive either t…

This study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) for people with advanced colorectal cancer that no longer responds to other therapies. About 700 adults with a specific marker (c-Met) on th…

This study looks at how well the drug Foslevodopa/Foscarbidopa works for people with early advanced Parkinson's disease. About 100 adults will receive the drug as a continuous infusion under the skin for up to 6 months. Researchers will track changes in daily 'off' time (when sym…

This early-stage trial tests a drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. Participants receive the drug b…

This early-stage study will enroll 12 healthy adults to see how different tablet versions of the drug emraclidine are absorbed into the body. Participants will take a single dose of each formulation and have blood samples taken. The study does not aim to treat any disease, only t…

This study looks at how consistently different labs measure a protein called FRa in ovarian cancer tissue samples. It uses archived biopsies from about 1,000 women with ovarian cancer. No new treatments or drugs are given—researchers simply compare test results from local and cen…

This study is the first time ABBV-1451 is given to humans. It aims to check the drug's safety, how the body processes it, and whether it triggers an immune response. About 90 healthy adults, including Japanese and Han Chinese participants, will receive a single dose. This is an e…

This study looks at tissue samples from 200 people with relapsed ovarian, fallopian tube, or primary peritoneal cancer to measure a protein called folate receptor alpha. The goal is to see how common high levels of this protein are at first diagnosis and after the cancer returns.…

This study tests how the drug risankizumab behaves in the body when given as a shot under the skin versus through a vein. It involves 60 healthy adults and aims to measure drug levels and any side effects. The results will help guide future dosing for patients with conditions lik…